Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD1003 in Demyelinating Neuropathies
NCT02967679Phase 2Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of biotin in chronic inflammatory demyelinating polyneuropathy (CIDP), Charcot-Marie-Tooth disease (CMT) and anti-myelin-associated glycoprotein neuropathy, sponsored by MedDay Pharmaceuticals. Primary endpoints: Motor Nerve Conduction Velocity at 48 weeks, Distal Latency at 48 weeks and 2 more. Started Dec 2016; status: completed.
02
Drugs
biotin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)Charcot-Marie-Tooth disease (CMT)anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on NCT02967679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967679.